Lenacapavir injection lowers HIV risk by 96% - Medical News Today
19 hours ago · Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown. Medical News Today Health Conditions
Twice-yearly shot proves successful at preventing HIV infection …
Jul 24, 2024 · Phase 3 trial data shows that a twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections. Two shots a year of a drug currently used to treat HIV...
Long-acting injectable lenacapavir continues to show promising …
Sep 26, 2024 · WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
An injectable HIV-prevention drug is highly effective - NBC News
Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...
New injection Lenacapavir reduces risk of HIV infection by 96 …
19 hours ago · A new HIV prevention method of injecting the drug called Lenacapavir just twice a year has shown groundbreaking results, better than daily oral medications. In a clinical trial called Purpose-2, led by Emory University and Grady Health System, the injectable reduced the risk of HIV infection by 96%.
New HIV drug can only offer hope of ending AIDS if all have …
GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
Sep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
Long-acting injectable lenacapavir proves effective in HIV …
Jul 26, 2024 · WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women. This represents a significant breakthrough in HIV prevention.
Gileads Twice Yearly Lenacapavir Demonstrated 100 Efficacy and ...
Jun 20, 2024 · PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada ® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and background HIV incidence (bHIV).
Gilead Lenacapavir cut HIV infections by 96% in trial
Sep 12, 2024 · Gilead ’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase-three trial data on lenacapavir sets the stage …